ZYNE
Zynerba Pharmaceuticals, Inc.
$0.42
Earnings Summary
Revenue | $0.09Mn |
Net Profits | $-9.15Mn |
Net Profit Margins | -10636.07% |
Highlights
Zynerba Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $0.09Mn in the Q1 2019. On a quarterly growth basis, Zynerba Pharmaceuticals, Inc. has generated 0% jump in its revenue since last 3-months.
Zynerba Pharmaceuticals, Inc.’s net profit jumped 25.67% since last year same period to $-9.15Mn in the Q1 2019. On a quarterly growth basis, Zynerba Pharmaceuticals, Inc. has generated -17.42% fall in its net profits since last 3-months.
Zynerba Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -10636.07% in the Q1 2019. On a quarterly growth basis, Zynerba Pharmaceuticals, Inc. has generated -17.42% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Zynerba Pharmaceuticals, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Current Year | -0.18 |
Highlights
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.18 - a 18.18% jump from last quarter’s estimates.
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.18.
Key Ratios
Key ratios of the Zynerba Pharmaceuticals, Inc. post its Q3 2022 earnings
Earning Per Share (EPS) | -0.2 |
Return on Assets (ROA) | -0.29 |
Return on Equity (ROE) | -0.55 |
Highlights
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) jumped 23.08% since last year same period to -0.2 in the Q3 2022. This indicates that the Zynerba Pharmaceuticals, Inc. has generated 23.08% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zynerba Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.29.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zynerba Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.55.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-11-08 | -0.7 | -0.47 | 32.86% |
2018-08-02 | -0.78 | -0.89 | -14.1% |
2019-03-11 | -0.65 | -0.44 | 32.31% |
2018-05-08 | -0.66 | -0.91 | -37.88% |
Company Information
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.
Organisation | Zynerba Pharmaceuticals, Inc. |
Headquarters | 80 West Lancaster Avenue, Devon, PA, United States, 19333 |
Employees | 28 |
Industry | Health Technology |
CEO | Armando Anido |
